BillionToOne, Inc.

NASDAQ:BLLN

Medical - Diagnostics & Research

Healthcare
$91.54 +0.84%

+$0.84 today

Market cap
$4.37B
Beta
0.90
P/E (TTM)
182.6
EPS (TTM)
$0.55
52W Low $61.96High $138.70

Volume 1.44M

Average 0.59M

BLLN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

BillionToOne, Inc.NASDAQ: BLLN

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development growth accelerates

Q2 FY2026 research & development of $17.32M rose 47.3% year over year, ahead of the +38.6% change in trailing-twelve-month research & development. Sequentially, it rose 17.9% from the prior quarter.

Context

  • Research & development amounted to 16.2% of revenue in FY2025, down 7.8 pp from a year earlier.
  • Research & development increased in 2 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether quarterly growth of +47.3% holds above the trailing-twelve-month pace of +38.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$17.32M+17.9% QoQ
Last fiscal yearDec 2025
$49.38M+34.9% YoY
LTMJun 2026
$59.21M+38.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.3%——
1 year+34.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
49.38M USD
Year-over-year change
+34.9%
2-year CAGR
+48.4%

Research & Development vs competitors

How BLLN compares with its peers on the latest reported figures

  • BLLN's LTM Jun 2026 research & development of $59.21M is the 7th highest of the 9 companies compared; the peer median is $99.89M.
  • Its year-over-year change of +38.6% is the 3rd highest of 9, against a peer median of +10.7%.
  • Research & development amounts to 14.9% of revenue for BLLN, versus a peer median of 17.9%.
BLLN Competitors Peer median
Research & Development for BLLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$787.38M +56.9%+25.4%29.1%
GHGuardant Health, Inc.LTM Sep 2026$386.67M +7.6%-0.9%30.2%
GRALGRAIL, Inc.LTM Jun 2026$190.99M -15.8%-15.9%115.6%
MYGNMyriad Genetics, Inc.LTM Mar 2026$106.4M -7.7%+7.7%12.8%
VCYTVeracyte, Inc.LTM Jun 2026$93.37M +31.8%+20.4%16.6%
WGSGeneDx Holdings Corp.LTM Jun 2026$83.32M +64.3%-5.8%18.3%
BLLNBillionToOne, Inc.LTM Jun 2026$59.21M +38.6%—14.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$55.69M +11.9%+23.1%17.4%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
Peer median (excluding BLLN) $99.89M+10.7%+7.3%17.9%

Competitors are the stored peer set for BLLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue71.73M152.58M305.11M
Cost of Revenue54.42M71.67M96.65M
Gross Profit17.31M80.92M208.46M
Gross Margin24.1%53.0%68.3%
Research & Development22.41M36.6M49.38M
Selling, General & Admin64.39M91.47M143.05M
Operating Expenses86.8M128.06M192.44M
Depreciation & Amortization6.46M11.69M11.91M
EBITDA(72.94M)(27.47M)19.76M
EBITDA Margin-101.7%-18.0%6.5%
Operating Income(69.5M)(47.15M)16.02M
Operating Margin-96.9%-30.9%5.3%
Interest Income3.46M5.82M7.75M
Interest Expense3.27M2.39M95K
Other Income / Expenses(13.18M)5.61M(8.26M)
Income Before Tax(82.67M)(41.54M)7.76M
Pre-Tax Margin-115.3%-27.2%2.5%
Income Tax Expense9K29K305K
Net Income(82.68M)(41.57M)7.45M
Net Margin-115.3%-27.2%2.4%
EPS (Basic)(1.85)(0.93)0.06
EPS (Diluted)(1.85)(0.93)0.06
Weighted Avg Shares44.72M44.72M45.8M
Weighted Avg Shares (Diluted)44.72M44.72M45.8M

BillionToOne, Inc.

NASDAQ:BLLN

Intrinsic Alpha fair value

Locked

Current Price

$91.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.